{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,26]],"date-time":"2026-08-26T17:22:21Z","timestamp":1787764941713,"version":"build-2784847793"},"reference-count":33,"publisher":"Ovid Technologies (Wolters Kluwer Health)","content-domain":{"domain":["lww.com","ovid.com"],"crossmark-restriction":true},"short-container-title":[],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>Crohn\u2019s disease is a chronic and progressive inflammatory disease of the gastrointestinal tract; whose symptoms recur and subside. This disease mainly affects the ileum and terminal colon and usually causes segmental, asymmetric, and transmural inflammation. Its clinical symptoms are variable, including diarrhea, abdominal pain, rectal bleeding, weight loss, and skin lesions. Due to the unknown causes of this disease, it is difficult to diagnose and manage it, especially in cases of silent Crohn\u2019s disease that does not have clear symptoms, and this has made the diagnosis of silent Crohn\u2019s a serious challenge for specialists. Unfortunately, today there is no specific guideline for the diagnosis and management of silent Crohn\u2019s disease, and the purpose of this research is to provide such a guideline. Two separate approaches were adopted: firstly, the evaluation of international articles (researchers\u2019 point of view) and the second part, the evaluation of the opinions of Iranian specialists active in the field of diagnosis and treatment of Crohn\u2019s patients (experts\u2019 point of view). in terms of Therefore, the opinions and discussions raised in international articles regarding diagnostic methods, clinical indicators, alternative methods in diagnosis, treatment methods, methods of monitoring treatment, and follow-up are reviewed, summarized, and compared with the opinions and performance of experts. Internally placed. According to experts\u2019 opinions, questions were designed based on scenarios of patients with special conditions. Then, the opinions of the country\u2019s most prominent internal medicine and gastroenterology specialists were recorded in person or by phone. Finally, the opinions were summarized and a proposed recommendation was created for the diagnosis of silent Crohn\u2019s disease. Mainly for the initial diagnosis of silent Crohn\u2019s depending on the condition of the disease, the diagnosis of aphthous lesions similar to Crohn\u2019s, in patients with high CRP and other inflammatory indicators or fecal calprotectin, the diagnostic recommendations were based on colonoscopy-based methods. Endoscopy (capsule) and especially ileocolonoscopy, fecal calprotectin assay, but no diagnosis is superior to histopathological findings. For treatment, steroid immunosuppressive drugs, mesalazine, budesonide, azathioprine, and sometimes surgery are useful. In cases where the intensity of the lesions is low, the use of non-steroidal anti-inflammatory drugs and acetylsalicylate recommended. However, there is often no need for therapeutic intervention and the lesions may have resolved spontaneously during follow-up. For the diagnosis of silent Crohn\u2019s disease, our proposed guideline can be of great help to physicians, as the most available tools are identified in diagnosis, disease monitoring, treatment, and follow-up. We recommend that the effectiveness of this guideline in the diagnosis and treatment of silent Crohn\u2019s disease be investigated by other researchers.<\/jats:p>","DOI":"10.4103\/ijpvm.ijpvm_13_24","type":"journal-article","created":{"date-parts":[[2025,7,30]],"date-time":"2025-07-30T13:00:26Z","timestamp":1753880426000},"update-policy":"https:\/\/doi.org\/10.1097\/lww.0000000000001000","source":"Crossref","is-referenced-by-count":0,"title":["Local Guidelines Regarding the Therapeutic and Diagnostic Management of Silent Crohn\u2019s Patients"],"prefix":"10.4103","volume":"16","author":[{"given":"Mohammad","family":"Rezaeisadrabadi","sequence":"first","affiliation":[{"name":"Gastroenterology and Hepatology Reasearch Center, Isfahan University of Medical Sciences, Isfahan, Iran"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Babak","family":"Tamizifar","sequence":"additional","affiliation":[{"name":"Gastroenterology and Hepatology Reasearch Center, Isfahan University of Medical Sciences, Isfahan, Iran"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Peyman","family":"Adibi","sequence":"additional","affiliation":[{"name":"Gastroenterology and Hepatology Reasearch Center, Isfahan University of Medical Sciences, Isfahan, Iran"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","published-online":{"date-parts":[[2025,7]]},"reference":[{"key":"R1-20250730","doi-asserted-by":"crossref","first-page":"1091330","DOI":"10.3389\/fmed.2022.1091330","article-title":"Factors associated with health-related quality of life in patients with Crohn's disease in Iran:A prospective observational study","volume":"9","author":"Karami","year":"2022","journal-title":"Front Med (Lausanne)"},{"key":"R2-20250730","doi-asserted-by":"crossref","first-page":"628","DOI":"10.1056\/NEJMra1909094","article-title":"Reframing immune-mediated inflammatory diseases through signature cytokine hubs","volume":"385","author":"Schett","year":"2021","journal-title":"New England Journal of Medicine"},{"key":"R3-20250730","doi-asserted-by":"crossref","first-page":"1741","DOI":"10.1016\/S0140-6736(16)31711-1","article-title":"Crohn's disease","volume":"389","author":"Torres","year":"2017","journal-title":"The Lancet"},{"key":"R4-20250730","doi-asserted-by":"crossref","first-page":"46","DOI":"10.1053\/j.gastro.2011.10.001","article-title":"Increasing incidence and prevalence of the inflammatory bowel diseases with time, based on systematic review","volume":"142","author":"Molodecky","year":"2012","journal-title":"Gastroenterology"},{"key":"R5-20250730","doi-asserted-by":"crossref","first-page":"22","DOI":"10.1038\/s41572-020-0156-2","article-title":"Crohn's disease","volume":"6","author":"Roda","year":"2020","journal-title":"Nature Reviews Disease Primers"},{"key":"R6-20250730","doi-asserted-by":"crossref","first-page":"144","DOI":"10.1093\/ecco-jcc\/jjy113","article-title":"ECCO-ESGAR Guideline for Diagnostic Assessment in IBD Part 1:Initial diagnosis, monitoring of known IBD, detection of complications","volume":"13","author":"Maaser","year":"2019","journal-title":"Journal of Crohn's and Colitis"},{"issue":"(Suppl 3)","key":"R7-20250730","doi-asserted-by":"crossref","first-page":"S1","DOI":"10.1136\/gutjnl-2019-318484","article-title":"British Society of Gastroenterology consensus guidelines on the management of inflammatory bowel disease in adults","volume":"68","author":"Lamb","year":"2019","journal-title":"Gut"},{"key":"R8-20250730","doi-asserted-by":"crossref","first-page":"384","DOI":"10.14309\/ajg.0000000000000152","article-title":"ACG clinical guideline:ulcerative colitis in adults","volume":"114","author":"Rubin","year":"2019","journal-title":"Official journal of the American College of Gastroenterology|ACG"},{"key":"R9-20250730","doi-asserted-by":"crossref","first-page":"1309","DOI":"10.1016\/j.cgh.2019.11.052","article-title":"Use of cross-sectional imaging for tight monitoring of inflammatory bowel diseases","volume":"18","author":"Allocca","year":"2020","journal-title":"Clinical Gastroenterology and Hepatology"},{"key":"R10-20250730","doi-asserted-by":"crossref","first-page":"481","DOI":"10.1038\/ajg.2018.27","article-title":"ACG clinical guideline:management of Crohn's disease in adults","volume":"113","author":"Lichtenstein","year":"2018","journal-title":"Official journal of the American College of Gastroenterology|ACG"},{"key":"R11-20250730","doi-asserted-by":"crossref","first-page":"735","DOI":"10.1111\/j.1572-0241.2001.03614.x","article-title":"Asymptomatic inflammatory bowel disease with special reference to ulcerative colitis in apparently healthy persons","volume":"96","author":"Sakata","year":"2001","journal-title":"The American journal of gastroenterology"},{"key":"R12-20250730","first-page":"45","article-title":"Gastrointestinal hypoalgesia in inflammatory bowel disease","volume":"33","author":"Coates","year":"2020","journal-title":"Annals of Gastroenterology"},{"key":"R13-20250730","first-page":"2254","article-title":"Silent Crohn's disease:asymptomatic patients with elevated C-reactive protein are at risk for subsequent hospitalization","volume":"21","author":"Click","year":"2015","journal-title":"Inflammatory bowel diseases"},{"key":"R14-20250730","doi-asserted-by":"crossref","first-page":"2665","DOI":"10.1097\/MIB.0000000000000935","article-title":"Silent Crohn's disease predicts increased bowel damage during multiyear follow-up:the consequences of under-reporting active inflammation","volume":"22","author":"Bhattacharya","year":"2016","journal-title":"Inflammatory bowel diseases"},{"key":"R15-20250730","doi-asserted-by":"crossref","first-page":"52","DOI":"10.1053\/j.gastro.2014.09.015","article-title":"Development of the L\u00e9mann index to assess digestive tract damage in patients with Crohn's disease","volume":"148","author":"Pariente","year":"2015","journal-title":"Gastroenterology"},{"key":"R16-20250730","doi-asserted-by":"crossref","first-page":"924","DOI":"10.1136\/bmj.39489.470347.AD","article-title":"GRADE:an emerging consensus on rating quality of evidence and strength of recommendations","volume":"336","author":"Guyatt","year":"2008","journal-title":"Bmj"},{"key":"R17-20250730","doi-asserted-by":"crossref","first-page":"465","DOI":"10.1007\/s10787-019-00595-4","article-title":"A randomised, double-blind, placebo-controlled trial of a multi-strain probiotic in patients with asymptomatic ulcerative colitis and Crohn's disease","volume":"27","author":"Bjarnason","year":"2019","journal-title":"Inflammopharmacology"},{"key":"R18-20250730","doi-asserted-by":"crossref","first-page":"1025","DOI":"10.1007\/s00384-017-2770-3","article-title":"Aspecific ileitis:Crohn's disease or not Crohn's disease?A prospective study","volume":"32","author":"Bezzio","year":"2017","journal-title":"International Journal of Colorectal Disease"},{"key":"R19-20250730","doi-asserted-by":"crossref","first-page":"1226","DOI":"10.1016\/j.gie.2010.08.029","article-title":"Isolated terminal ileal ulcerations in asymptomatic individuals:natural course and clinical significance","volume":"72","author":"Chang","year":"2010","journal-title":"Gastrointestinal endoscopy"},{"key":"R20-20250730","doi-asserted-by":"crossref","first-page":"1341","DOI":"10.1097\/PAS.0b013e3181ad25b6","article-title":"Isolated asymptomatic ileitis does not progress to overt Crohn disease on long-term follow-up despite features of chronicity in ileal biopsies","volume":"33","author":"Courville","year":"2009","journal-title":"The American journal of surgical pathology"},{"key":"R22-20250730","doi-asserted-by":"crossref","first-page":"1455","DOI":"10.1093\/ecco-jcc\/jjab030","article-title":"Prevalence and progression of incidental terminal ileitis on non-diagnostic colonoscopy:a systematic review and meta-analysis","volume":"15","author":"Agrawal","year":"2021","journal-title":"Journal of Crohn's and Colitis"},{"key":"R23-20250730","doi-asserted-by":"crossref","first-page":"E539","DOI":"10.1055\/s-0043-100688","article-title":"Symptomatic isolated terminal ileal ulcers:etiology and clinical significance","volume":"5","author":"Mehta","year":"2017","journal-title":"Endoscopy International Open"},{"key":"R24-20250730","doi-asserted-by":"crossref","DOI":"10.17235\/reed.2022.9423\/2022","article-title":"Isolated jejunal Crohn's disease:a challenging diagnosis","author":"Sequeira","year":"2022","journal-title":"Revista Espanola de Enfermedades Digestivas:Organo Oficial de la Sociedad Espanola de Patologia Digestiva"},{"key":"R25-20250730","doi-asserted-by":"crossref","first-page":"522","DOI":"10.3892\/mmr.2014.2180","article-title":"Faecal calprotectin as a novel biomarker for differentiating between inflammatory bowel disease and irritable bowel syndrome","volume":"10","author":"Chang","year":"2014","journal-title":"Molecular medicine reports"},{"key":"R26-20250730","doi-asserted-by":"crossref","first-page":"435","DOI":"10.1093\/qjmed\/hci069","article-title":"Faecal calprotectin in the assessment of Crohn's disease activity","volume":"98","author":"Gaya","year":"2005","journal-title":"Qjm"},{"key":"R27-20250730","doi-asserted-by":"crossref","first-page":"101","DOI":"10.1159\/000513473","article-title":"Elevated faecal calprotectin in patients with a normal colonoscopy:does it matter in clinical practice?A retrospective observational study","volume":"6","author":"Hovstadius","year":"2021","journal-title":"Inflammatory Intestinal Diseases"},{"issue":"(Suppl 3)","key":"R28-20250730","doi-asserted-by":"crossref","first-page":"s28","DOI":"10.7861\/clinmedicine.16-3-s28","article-title":"Faecal calprotectin\u2013the Crohn's disease activity predictor of the future","volume":"16","author":"Ramphul","year":"2016","journal-title":"Clinical Medicine"},{"key":"R29-20250730","doi-asserted-by":"crossref","first-page":"342","DOI":"10.1093\/ecco-jcc\/jjz155","article-title":"Impact of Aphthous Colitis at Diagnosis on Crohn's Disease Outcomes","volume":"14","author":"Delattre","year":"2020","journal-title":"J Crohns Colitis"},{"key":"R30-20250730","doi-asserted-by":"crossref","first-page":"1046","DOI":"10.1259\/bjr.73.874.11271896","article-title":"Crohn's disease of aphthous type:serial changes in intestinal lesions","volume":"73","author":"Matsumoto","year":"2000","journal-title":"Br J Radiol"},{"key":"R31-20250730","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.jcmgh.2022.09.011","article-title":"Pathogenesis of Fistulating Crohn's Disease:A Review","volume":"15","author":"McGregor","year":"2023","journal-title":"Cell Mol Gastroenterol Hepatol"},{"key":"R32-20250730","article-title":"Impact of Crohn's Disease Therapies on Histology in Randomized Controlled Trials:Systematic Review With Meta-analysis","author":"Roseira","year":"2022","journal-title":"Inflamm Bowel Dis"},{"key":"R33-20250730","doi-asserted-by":"crossref","first-page":"415","DOI":"10.1136\/gutjnl-2014-307649","article-title":"Identification of an anti-inflammatory protein from Faecalibacterium prausnitzii, a commensal bacterium deficient in Crohn's disease","volume":"65","author":"Qu\u00e9vrain","year":"2016","journal-title":"Gut"},{"key":"R34-20250730","doi-asserted-by":"crossref","first-page":"1039","DOI":"10.1136\/gutjnl-2015-310746","article-title":"Fungal microbiota dysbiosis in IBD","volume":"66","author":"Sokol","year":"2017","journal-title":"Gut"}],"container-title":["International Journal of Preventive Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.ovid.com\/10.4103\/ijpvm.ijpvm_13_24","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,26]],"date-time":"2026-08-26T16:52:19Z","timestamp":1787763139000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.ovid.com\/10.4103\/ijpvm.ijpvm_13_24"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,7]]},"references-count":33,"URL":"https:\/\/doi.org\/10.4103\/ijpvm.ijpvm_13_24","relation":{},"ISSN":["2008-7802","2008-8213"],"issn-type":[{"value":"2008-7802","type":"print"},{"value":"2008-8213","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,7]]},"assertion":[{"value":"2024-01-07","name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2024-09-30","name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}}]}}